Antibe Therapeutics

Antibe Therapeutics Inc.
	Logo of Antibe Therapeutics
Type	Publicly traded corporation
Traded as	TSX: ATE
Industry	Pharmaceuticals
Headquarters	Toronto, Canada
Key people	Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer
Website	www.antibethera.com

Antibe Therapeutics is a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology.[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.[2] On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug.[3]

Products

The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[4] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[5] Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to other types of chronic pain and diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.[6]

In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[7] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[8] In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.[9]

On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for ATB-346.[10] On June 1, 2020, Antibe announced positive results for ATB-346 (now known by its International Nonproprietary Name, otenaproxesul) in its final Phase 2 trial, a dose ranging, efficacy study.[11] The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2021.[12]

On November 12, 2020, Antibe Therapeutics has moved to the TSX.

Antibe's products have not yet been approved by the US Food and Drug Administration.

People

Antibe's science advisory board:[13]

Andre G. Buret, Professor, University of Calgary, Canada
Giuseppe Cirino, PhD, Professor, University of Naples, Italy
Gilberto de Nucci, MD, PhD, Professor, University of Sao Paulo, Brazil
Peter B. Ernst, DVM, PhD, Professor, UCSD, San Diego, USA
Derek Gilroy, PhD, Professor, University College, London, UK
Richard H. Hunt, MD, Emeritus Professor, McMaster University, Canada
Louis Ignarro, PhD Professor, UCLA, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
Daniel K. Podolsky, MD, President, University of Texas Southwestern Medical Center, USA
William Sessa, PhD, Professor, Yale University, USA
Philip M. Sherman, MD, Professor, University of Toronto, Canada

Antibe's board of directors:[14]

Chair - Walt Macnee, Vice Chair, MasterCard International[15]
Roderick Flower, Professor Emeritus, Barts and The London School of Medicine and Dentistry
Dan Legault, CEO, Antibe Therapeutics
Robert Hoffman, former CFO, Heron Therapeutics; Director, public biotechnology companies
Amal Khouri, VP Business Development, Knight Therapeutics[16]
Jennifer McNealey, VP Investor Relations and Strategy, Calithera Biosciences
John L. Wallace, Chief Scientific Officer, Antibe Therapeutics
Yung Wu, CEO, MaRS Discovery District[17]

References

External links

Official website

Biotechnology Focus: The Need for a Safer NSAID: Can Antibe Therapeutics Deliver One?
Third International Conference on Medical & Biological Uses of Hydrogen Sulfide

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] ttp://www.antibethera.com

[2] ttps://www.bloomberg.com/research/stocks/news/article.asp?docKey=600-201602021810BIZWIRE_USPRX____BW6697-1&ex=true&ticker=MNK

[3] ttps://www.acsh.org/news/2020/08/05/antibes-non-opioid-pain-drug-otenaproxesul-looks-good-phase-iib-trials-14951

[4] ttps://antibethera.com/science/why-h2s/

[5] "H2S and Inflammation: An Overview". Handb Exp Pharmacol: 165–180. 2015. doi:10.1007/978-3-319-18144-8_8. PMID 26162834.

[6] British Journal of Pharmacology "A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug". Br J Pharmacol. 177 (4): 769–777. February 2019. doi:10.1111/bph.14641. PMC 7024706. PMID 30834513.

[7] ttps://www.wsj.com/article/PR-CO-20140505-901386.html

[8] ttp://www.marketwatch.com/story/antibe-therapeutics-announces-first-human-dose-of-atb-346-in-phase-i-clinical-trial-2014-06-26

[9] ttps://antibethera.com/news/antibe-therapeutics-provides-an-update-on-its-data-review-and-corporate-strategy/

[10] ttps://antibethera.com/news/antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346/

[11] ttps://antibethera.com/news/antibe-therapeutics-announces-positive-top-line-data-from-phase-2b-dose-ranging-efficacy-study-for-atb-346/

[12] ttps://antibethera.com/news/antibe-therapeutics-provides-corporate-update/

[13] ttps://antibethera.com/about-us/scientific-advisory-board/

[14] ttps://antibethera.com/about-us/board-of-directors/

[15] ttp://investorrelations.mastercardintl.com/phoenix.zhtml?c=148835&p=irol-govBio&ID=144740

[16] ttps://www.gud-knight.com/category/management-team/

[17] ttps://marsdd.com/about/